---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-065107"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2023-05-26T23:59:59+00:00"
generated_at: "2026-06-14T13:41:27.574980+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Acura receives $150K loan from 66% owner AD Pharma; warns of possible shutdown if no more funding

## Summary
- Loan from Abuse Deterrent Pharma adds to $2.32M note, total debt $3.47M at 5.25%, due Dec 31, 2023.
- Also received $235K from CARES Act employee retention credit; funds expected to last through June 2023.
- If additional financing not secured by end of June 2023, may scale back operations or seek bankruptcy.
- AD Pharma owns ~66% of common stock; entity controlled by Mr. Schutte who holds ~14% directly.
- Overdue amounts bear interest at 7.5% per annum after 5-day grace period.

## SEC filing metadata
- accession: 0001104659-23-065107
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2023-05-26T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465923065107/0001104659-23-065107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465923065107/tm2317061d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-065107
- JSON: https://secwatch.observer/filing/0001104659-23-065107.json
- Plain text: https://secwatch.observer/filing/0001104659-23-065107.txt

## Key facts
- Debt Financings
  ACURA PHARMACEUTICALS, INC incurred loan of $150,000 loan with Abuse Deterrent Pharma, LLC at 5.25% maturing December 31, 2023.
  - Instrument: loan
  - Principal: $150,000 loan
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Rate: 5.25%
  - Maturity: December 31, 2023
  - Event: incurrence
  source text: On May 19, 2023 we received a $150,000 loan from Abuse Deterrent Pharma, LLC ("AD Pharma").
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465923065107/0001104659-23-065107-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.